Tirzepatide (5 mg Vial) Dosage Protocol

Dosing & Reconstitution Overview

Tirzepatide (research code LY3298176) is a 39-amino-acid single-molecule dual agonist studied for its combined activity at the GLP-1 and GIP receptors. The figures below are compiled strictly for laboratory and educational reference — they describe how the compound was handled and dosed across published trials, not a recommendation for use in humans or animals.

For a 5 mg vial, adding 2.0 mL of bacteriostatic water yields a concentration of 2.5 mg/mL (2,500 mcg/mL). At that fill, each U-100 insulin unit equals 0.01 mL and delivers 25 mcg, so a single 5 mg vial holds exactly one 5 mg study dose. Drawing 25 units (0.25 mL) measures out 2.5 mg, which keeps the arithmetic clean across the titration steps.

Standard (Gradual) Titration Schedule

The gradual schedule mirrors the slow dose-escalation design used in the registration trials, where the weekly amount was stepped up roughly every four weeks to manage gastrointestinal tolerability.

Reconstitution Steps

1. Let the sealed lyophilized vial and the bacteriostatic water reach room temperature, then wipe both stoppers with an alcohol swab.
2. Draw 2.0 mL of bacteriostatic water and inject it slowly down the inside wall of the vial — never directly onto the powder pellet.
3. Swirl gently until fully dissolved. Do not shake; aggressive agitation can shear the peptide.
4. The solution should be clear and colourless. Label the vial with the concentration (2.5 mg/mL) and the reconstitution date.
5. Store upright under refrigeration between uses and draw subsequent volumes with a fresh sterile syringe each time.

Advanced (Aggressive) Titration Schedule

The advanced schedule continues to the 15 mg ceiling evaluated in the trial program, where the highest cohort recorded the largest average weight reductions. It carries the escalation past the 10 mg step into the upper maintenance band.

Supplies Needed

• Tirzepatide vials (5 mg): ~6 vials for an 8-week gradual run; ~12 vials for a 12-week run; ~20 vials for a full 16-week escalation to 10 mg.
• Insulin syringes (U-100, 1 mL): ~12 for 8 weeks; ~24 for 12 weeks; ~40 for 16 weeks (one fresh syringe per draw, two at the highest steps).
• Bacteriostatic water (10 mL): two bottles for an 8-week run, three for 12 weeks, four for 16 weeks.
• Alcohol swabs: a single 100-count box comfortably covers an 8–16 week schedule.

Protocol Overview

• Research goal: model metabolic weight-regulation and glycaemic control via simultaneous GLP-1 and GIP receptor activation.
• Schedule: once-weekly subcutaneous administration in the published model.
• Dose band: 2.5–10 mg standard, up to 12.5–15 mg in aggressive arms.
• Fill: 5 mg lyophilized, reconstituted to 2.5 mg/mL with 2 mL diluent.
• Storage: −20 °C dry; 2–8 °C once reconstituted.

Dosing Protocol Notes

• Begin at the lowest 2.5 mg step and hold each level for about four weeks before escalating.
• Keep administration on a fixed weekly cadence and the same day where possible for steady exposure modelling.
• Escalate only after tolerability is established at the prior step.
• With a roughly 5-day half-life, once-weekly dosing maintains relatively steady exposure between administrations.

Storage Instructions

Keep sealed lyophilized vials at −20 °C, in dry and dark conditions, where stability extends for many months. Once reconstituted, refrigerate at 2–8 °C and use within about 28 days. Do not freeze the reconstituted solution, allow it to warm slightly before drawing, avoid repeated freeze-thaw cycles, and aliquot if a vial will be sampled many times.

Important Handling Notes

• Use a sterile syringe for every draw and never re-enter the vial with a used needle.
• Rotate sampling/handling technique to keep the stopper intact.
• Split larger volumes across syringes when a single dose exceeds 1 mL.
• Document each draw — date, volume, remaining material — for reproducibility.

How Tirzepatide Works

Tirzepatide is a synthetic 39-amino-acid peptide engineered to act as a dual agonist at two incretin receptors at once: GLP-1 and GIP, both of which are involved in glucose-dependent insulin secretion and appetite regulation. The combined activity enhances insulin release, suppresses glucagon, slows gastric emptying and reduces appetite. A fatty-acid modification extends its half-life to roughly five days, which supports once-weekly dosing in trials and distinguishes it from single-receptor (GLP-1-only) agonists in the comparative literature.

Reported Benefits & Side Effects

Benefits observed in trials

• Average body-weight reduction of roughly 15–21% at the higher doses in the obesity program.
• Substantial HbA1c reductions across the Type 2 diabetes trials.
• Up to ~11 kg greater weight loss than GLP-1-only comparators over 26 weeks at higher doses.
• Improvements in lipid profile and blood pressure observed alongside weight reduction.

Side effects reported

• Dose-dependent gastrointestinal effects — nausea, diarrhoea, vomiting and constipation — most common during escalation.
• Generally mild-to-moderate and reduced by slower titration.
• Occasional mild injection-site redness or irritation.

Supporting Lifestyle Factors (Research Context)

• Protein-forward, micronutrient-dense nutrition in the published study designs.
• Combined resistance and aerobic activity to preserve lean mass.
• Adequate sleep, stress management and hydration as standard trial controls.

Injection Technique (Reference Only)

• Clean the vial stopper and site with alcohol swabs and let them dry.
• Pinch a skinfold and insert subcutaneously at a 45–90° angle depending on needle length; aspiration is not required for subcutaneous work.
• Inject slowly and steadily; split volume across sites when a dose exceeds a comfortable single injection.
• Rotate sites systematically (abdomen, outer thighs, upper arms) and dispose of sharps in an approved container.

References

Related Protocols